Phase I clinical study of Bruton's tyrosine kinase inhibitor (BTKi) HBW-3220 capsules in patients with relapsed/refractory (R/R) B-cell non-Hodgkin lymphoma (B-NHL)
Conferences
- Overview
- Research
- Identity
- Additional Document Info
- View All
Overview
status
publication date
- April 1, 2024
has subject area
- 1112 Oncology and Carcinogenesis (FoR)
- Oncology & Carcinogenesis (Science Metrix)
published in
- Cancer Research Journal